The Motley Fool··Reuben Gregg BrewerPfizer's 6.3% Yield Hinges on GLP-1 Drug Data, Patent Cliff Challenges
Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.
PFELLYNVOdividend yieldclinical trial results